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ABSTRACT  
The stability of a new drug substances and new drug products is a vital parameter which may affect purity, safety & potency. Changes in drug 
stability can threat patient safety by formation of toxic degradation products or deliver to lower dose than expected. Therefore it is to know the 
purity profile & behaviour of a drug substances under the various environmental condition.  Forced Degradation studies show the chemical 
behavior of the molecule which in turn helps in the  development of  new formulation & package . Degradation study is required to the design of 
a regulatory compliant stability program for the both drug substances & products, and formalized as a regulatory requirement in ICH Guideline 
Q1A in 1993. Forced degradation studies (chemical and physical stress testing) of new chemical entities and drug product which is required to 
develop and demonstrate the specificity i.e stability indicating method. Forced degradation studies used to determination of the degradation 
pathways and degradation product of drug substances i.e during storage, development, manufacturing and packaging Thus , this review 
discusses the current trends in performance of forced degradation studies by provide the information about strategy for conducting the studies 
of forced degradation 
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Introduction 
Forced degradation is a technique which means different 
stress condition applied to the drug substance and product. 
These studies also known as stress degradation and stress 
testing. These studies used for demonstrate stability of 
molecules under accelerated condition. Stability of molecules 
to help in selecting proper formulation, packaging and 
storage condition and also shelf life which is required for 
regulatory documentation. Forced degradation process, 
general condition like light, humidity, oxidation and heat. As 
per International Committee for harmonization (ICH) and 
FDA guidelines. Two type of studies i.e long term which is 
duration of study is about 12 Months, while accelerated 
stability studies about 6 Months. Intermediate stability 
studies about 6 months at milder condition than accelerated 
because the one can identify and separate the degraded 
product but its take a more time. Forced degradation detect 
the under different analytical equipment used i.e. HPLC, UV 
and HPLC photodiode array detector (PDA) used. [1] 
 
Needs for forced degradation studies 
Forced degradation studies are more important belongs to 
following aspect. [1-2] 
1) To studies the chemical beviours. 
2) To detect the degradation pathways. 
3) To solve the problem related to stability. 
4) To detect the structure of decomposition product. 
5) To develop the method and detect stability.  
6) Forced degradation is determination of instrinsic 
stability of drug in drug substanes and drug product. 
7) For required the production of stable formulation. 
8) To establish a degradation profile under ICH condition. 
Regulatory Guidelines 
Many guidelines are mentioned about the forced 
degradation like ICH (International Committee for 
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harmonization), FDA (Food and drug administration), EMA 
(European Medicines Agency), USP (United States 
Pharmacopeia), JP (Japanese Pharmacopoeia), and ANVISA 
(AgenciaNacional de Vigilancia Sanitaria). These guidelines 
also explained about forced degradation studies. [7-20] 
ICH Guidelines 
In ICH guidelines discuss about Forced degradation studies 
which is ICH Q1A, Q1B,  & Q2B, Q3A , Q3B, M4Q(R1). 
ICH Q1A – Testing of Stability for New drug molecules & 
Products. 
Determine the Instrinsic Stability of drug using these 
guidelines. Section 2.1.2 of Q1A guidelines. (Under Section 
ICH Q1A – Testing of Stability for new drug molecules & 
Products). These guidelines are essential in desingning 
method for determining the stability of drug.According to 
Q1A, degradation depends on drug molecules and drug 
products. To conduct the forced decomposition analyses on 
drug substances & Product s at several accelerated 
conditions were mentioned. Those conditions were effect of 
humidity (   % Relative humidity), temperature, 
oxidation, and photolysis & rang of pH (solution / 
suspension). [7] 
ICH Q1B – Photostability Testing of New drug substances 
and drug products 
This is used for estimation of photostability nature of drug 
molecules in the development stage. These guidelines 
provide information of how to assess the photo stability of 
molecules under the study for stability studies. [11] 
ICH Q2B – Validation of analytical procedures: 
Methodology 
These guidelines provide the knowledge about the protocols 
to be followed by validation of different analytical protocols. 
Sample usages for forced degradation studies mentioned in 
ICH Q2B, Part II, Section 1.2.2. Samples should be to stress 
under different accelerating condition like heat & humidity 
used for determination of specificity. In additional, essesntial 
for the quantitative determination of the degradation 
produced. [11-14] 
ICH Q3 Impurities in New drug substances 
These guidelines provide the knowledge about the 
determination of contaminants present in new drug 
molecules. In these Section insights about different aspect 
like identification, types & specification of impurities, 
analytical protocols & report. Most important, if the 
impurities are either completely absent or present in trace 
amounts in new batch of drug molecule is validation of 
chromatographic assays. In case of trace molecules, stability 
limit should be more than 90% and hence about 10% 
degradation is sufficient. [17] 
ICH Q3B – Impurities in New Products 
These guidelines provide knowledge about analytical 
procedures. It is essential for an analytical procedure to 
validate the specific or non - specific degradation products 
under various stress conditions. [18-19] 
ICH M4Q (R1) – The common technical document for the 
registration of pharmaceuticals for human use: Module 
3: Quality 
This document guideline provides knowledge about types of 
studies performed, procedures used & outcomes of the 
studies. In conclusion, it provides the condition of storage, 
storage life & the date for reassessment. Outcomes of 
stability analysis covers in Section 3.2.S.7.3.Results give in 
form of tabular, graphic, or narrative format & it also 
provide the analytical procedures along with the validation 
data. 
FDA Guidelines (Food and drug administration) 
This guideline provides information about the photo 
stability analysis of newer drug molecules & products (Q1B). 
According to the FDA, forced degradation studies should be 
conducted in normal development condition. It mentions the 
degradation pathway of samples when exposed to light. 
These guidelines also help to develop SIM & summarize the 
data of validation which are confirmatory studies. Section of 
these guidelines 211.166(a) (3), a SIM should be highly 
specific & it should be able to quantify the amount of active 
ingredient present, if these types of degradation products 
obtain and other components present in dosage form 
without any interference under stress condition.these stress 
condition essential for forced degradation studies are pH, 
temperature & oxygen. [8-9] 
EMA Guidelines (European Medicines Agency) 
These guidelines essential for chemistry of active 
substances. It mentions the data for type of studies 
performed, procedures used, outcomes thus obtained from 
the analysis. This guideline explains about the stability 
testing for API & dosage form in section 2.1.2. It also 
includes the data of retest date & expiry date of substances. 
It also determined the development analytical method, 
validation of method, degradation pathways, & instrinsic 
stability. It also conducting stability studies for sensitive 
compound like photosensitive & hygroscopic drug. [15-19] 
USP Pharmacopoeia: validation of compendia 
procedures 
This guidelines provide the information about the if 
degradation standard or   contaminats are not available, the 
specificity should be estimated in comparison of the data 
with the results obtained formanalytes ( degradation 
product or contaminats ) by using an alternative procedure 
under the same accelerated condition. [13] 
Japanese Pharmacopoeia 
This guideline states that the proposed method should be 
specific, to be able to identify & in the sample detect the 
amount of analyte present. For the comparative studies, 
sample will be exposed in stress condition & for further 
studies degradation products may be used if reference 
standard are not available. 
ANVISA (National Health Surveillance agency) 
This guideline provides information about the requirements 
relates to stability & forced degradation.these guideline 
protect from production regarding to risk caused & uses of 
various drug products. It was developed to promote public 
health. It also promotes the states, districts & municipalities, 
according to the Brazilian unified health system principles, 
so to increase the quality of life of the people. 
Time to perform degradation 
It is know to how to perform forced degradation studies & 
when to perform forced degradation studies for 
development for new drug substances & new drug products. 
According to FDA guidelines state that stress testing can be 
performe in phase III of regulatory submission process. 
Stress studies can be done in various pH solutions, i.e. 
presence of light, oxygen and at various increasing 
temperature & humidity to determine the stability of 
substances & drug product. [1-6] 
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Limits for Forced degradation studies 
Most of regulatory guidelines mentioned about limits of 
degradation i.e 5% -20% accepted criteria for validation of 
chromatographic assays. Stability should be more than 90% 
&about hence 10% enough for degradation. In general, for 
the observing drug product stability, spiked sample mixture 
of know degradation drug substance & drug products are 
used, which determining the product that are monitored 
during the degradation. [8-20] 
Sources of degradation products 
Degradation is one of the sources for impurities. Under  
various stress condition like Heat, humidity, isolation, pH, 
Storage & transportation processes , drug molecules under 
the degradation due to chemical instability. Forced 
degradation should be carried out through different 
pathways like oxidation, heat, photolysis, and hydrolysis. [1-2] 
Plan for selection of forced degradation condition 
Instrinsic stability of drug substance & drug product should 
be determined by using normal various conditions like pH & 
High temperature. Later than, drug molecule were targeted 
to additional stress to study the stability. To study the forced 
degradation, the solution including the sample was refluxed 
for a particular time. During that time, if degradation 
substance & product were monitored, the process would be 
stopped, further identification, isolation & monitored 
degradation product will be carried out. If no degradation 
monitored, the reaction time would be enhance to monitor 
any signs of degradation because the increasing of time. [1-2] 
Forced degradation studies used by following condition 
presented in Table 1 & Figure 1. 
 
Table 1: Condition used for Forced degradation studies 
Types for Degradation Experimental condition Storage condition Sampling time   (days) 
 
Hydrolysis 
Contol API ( no acid/ base) 40 oC , 60 oC 1,3,5 
0.1 M HCL 40 oC , 60 oC 1,3,5 
0.1 M NaOH 40 oC, 60 oC 1,3,5 
Base control ( no API) 40 oC, 60 oC 1,3,5 
PH: 2,4,6,8 40 oC, 60 oC 1,3,5 
 
Oxidation 
3% H2O2 25 oC, 60 oC 1,3,5 
Peroxide control 25oC , 60  oC 1,3,5 
Azobisisobutyronitrile (AIBN) 40 oC , 60 oC 1,3,5 
AIBN control 40 oC, 60 oC 1,3,5 
 
Photolysis 
Light 1x ICH NA 1,3,5 
Light 1x ICH NA 1,3,5 
Light control NA 1,3,5 
 
 
Thermolysis 
Heat chamber 60 oC 1,3,5 
Heat chamber 60 oC/75% RH 1,3,5 
Heat chamber 80  oC 1,3,5 
Heat chamber 80 oC/75% RH 1,3,5 
Heat chamber Room temp 1,3,5 
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Figure 1: Diagrammatic representation of degradation studies of drug substance & product under various stress 
condition 
Forced Degradation Condition 
Hydrolysis Condition 
This forced degradation condition is one of the most 
common chemical reaction over the wide range of pH. This 
chemical reaction decomposition by water. These forced 
degradation condition study under the acidic and basic 
condition. It involves catalysis of  ionization functional  
group present  in the molecule.In hydrolysis drug substance 
is exposure by acidic or basic condition.In acidic condition  
conc hydrochloric acid or sulfuric acid (0.1-1M) and  sodium 
hydroxide or potassium hydroxide (0.1 – 1M) for basic 
condition. If the compound is poorly soluble in water so then 
used the co solvent dissolve in HCL or NAOH. The selection 
of co solvent depends on drug substances structure. Forced 
degradation trial is normally started at room temperature 
(500C–700C) is applied. It shoud not exceed more than 7 
days. After that degraded sample neutralized by using 
suitable acid, Base or buffer, to avoid other decomposition. 
[1-6] 
Oxidation Condition 
Hydrogen peroxide mostly used for oxidation of drug 
substance in strees testing studies but other oxidizing agent 
like, metal ion, oxygen and radicals initiators (eg. 
Azobiosisbutyronitrile, AIBN) can be used. Selection of 
oxidizing agents its depends on concentration, & drug 
substance. Hydrogen peroxide is reported the solution 0.1-
3% at neutral pH and room temperature for 7 days. These 
conditions involve the electron transfer mechanisms to form 
reactive anion and cations. Amine, sulfide and phenols are 
able to electron transfer oxidation to give N – oxide, 
hydroxylamine, sulfonic and sulfoxide. [1-6] 
Photolytic Condition 
The photo stability testing drug substances mostly evaluated 
to illuminate that light exposure does not result in 
unacceptable change. These condition most of exposure to 
UV or fluorescent condition. This condition recommended 
for photo stability testing is describing ICH guideline. Sample 
of drug substances and solid / liquid drug product should be 
exposed to a minimum of 1.2 million 1X h and 200 W 
h/m2light. The most of accepted wavelength of light is in the 
range of 300- 800nm to cause the photolytic degradation. 
The maximum demonstrate recommended are 6 million 1 x 
h. photolytic conditions can include photo oxidation by free 
radical mechanism. Fictional group such as chlorides, weak 
C-H and O-H, sulfides and polyenes are likely introduce drug 
photosensitivity. [11] 
Thermal condition 
 Thermal degradation (eg. dry heat and wet heat) should be 
carried out at various strenuous conditions than 
recommended ICH Q1A short testing condition. Sample of 
solid state drug substances and drug product should be dry 
heat & wet heat, as well as liquid drug product should be 
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exposed dry heat. Studies may be conducted at higher 
temperature for shorter period. Effect of temperature on 
thermal degradation of substances studies through the 
Arrhenius equestion: 
K = A e -Ea/RT 
Where K is Specific reaction rate, A is Frequency factor, Ea is 
energy of activation, R is gas constant (1.987cal/ deg mole) 
and T is absolute temperature. Thermal degradation study is 
carried out 40-80 0C. [7] 
Factors affecting Degradation 
Below to the various factors which cause degradation of 
drug substances. [1] 
Moisture 
Water soluble substances may get dissolved, if the presence 
of moisture .this leads to physical and chemical changes 
within the molecule. 
Excipient 
It was observed that some excipient may contain high 
content of water. This moisture may leads to increase water 
level in formulation which later affects the stability of the 
drug. In some cases, chemical photolytic decomposition can 
be tested by comparing its stability in the presence of light 
and stability when stored under dark. Photo labile 
compound should be stored in amber glass containers and 
should be stored in dark .interaction that occurs between the 
excipient and the drug material often results in decreased 
stability. 
Temperature 
Changes in temperature at time its show deleterious effect 
on the stability of the drug. Increase in temperature usually 
causes increase the rate of drug hydrolysis. 
pH 
pH shows a significant effect on the degradation rate of 
drugs by hydrolysis. To reduce this effect, formulation of the 
drug is carried out using buffer solution of pH with 
maximum stability. 
Oxygen 
In the presence of oxygen to increase the oxidation. In the 
presence of oxygen cause increased rate of decomposition 
.stabilized by using purging nitrogen or carbon dioxide in the 
storage in container. 
Light 
Some drug is photo labile and tends to decompose when 
they are exposed to light. Hydrolysis drug molecules are 
dissolved in 0.1-1 M of potassium hydroxide or sodium 
hydroxide. Sample treated 2 – 7 days at room temperature. 
Treated sample were neutralized with relevant acid or base 
to prevent additional degradation. 
 
Table 2:- Below the some drugs studies results reported 
S.N. Drugs Name Study results 
1 Aceclofenac Na This drug Stable at dry it or below 800C and in the absence of light 
2 Diacerein This drug Unstable at base  hydrolysis, photolytic, and thermal conditions it remains stable 
under acid hydrolytic and oxidative stress condition 
3 Proteins This drug Unstable at photolytic conditions. Secondary packing is required to protect from 
light 
 
4 
 
Idarubicin 
Drug degradation observed in hydrolysis and oxidative stress condition. In oxidative stress 
condition and base hydrolysis, two degrading were produced, & in acid hydrolysis, one 
degrading was produced. 
 
5 
 
Valsartan 
This drug is unstable at acid stress condition and it produced three degradation products.2 
methyl-N-{[2’-( 1H –tetrazol-5-yl)biphenyl 3yl]methyl}propan-1-amine and N-methyl-N-
{[2’-91H-tetrazol-5-yl)biphenyl-3-yl]methyl} butanamide were produced due  to oxidative 
stress. 
6 Meloxicam & 
piroxicam 
This drug stable at thermal stress & unstable at hydrolytic, oxidative and photolytic stress 
condition. 
7 Tetrabenazine In base condition, poor degradation was occurs, but in acidic condition, more degradation 
had observed. 
8 Wheat straw In higher temperature, aromatic aldehydes were produced as degrades. 
 
9 
 
Anastrozole 
In alkaline hydrolysis & oxidative stress, drug molecule degraded and two degrades were 
produced. Drug impurities were characterized as 2, 2’-(5-((1H-1, 2, 4-triazol-1-yl) methyl)-
1, 3,-phenylene-2-yl) phenyl)-2methylpropanoicacid (monoacid). 
10 Ivabradine Ivabradine drug was unstable at acid –alkaline hydrolysis condition & five degradation 
products were produced at hydrolytic condition 
11 Amlodipine It was stable at thermal stress condition; in acidic stress two degrades & basic stress four 
degradative products & in oxidative stress condition one degradation product was 
produced. 
12 Lisinopril This drug was unstable at acid hydrolytic condition and four degradation products were 
produced. 
13 Midazolam maleate Unstable at acid hydrolytic & thermal stress condition. 
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14 Saikosaponin This drug under the acid hydrolysis, two degradant were produced; these impurities 
characterized as SS-B2 & hydroxysaikosaponin A. 
15 Moxidectin Its shows good stability under the thermal stress condition; at base hydrolysis two 
degradans produced which were characterized as 2-epi and 2,3 isomers 
16 Lansoprazole This drug in acid hydrolytic condition, one degradation product was produced & it was 
identified as 1-methyl-10-thioxo-10H-4a, 5, 9b-triaza-indeno [2, 1-a] inden-2one. 
17 Piracetam This drug stable under all condition except base stress condition .In base condition, one 
degradation product was occurred. 
18 Dexlansoprazole This drug under the oxidation stress condition, one degradation product was produced & 
characterized by 1-(1H- benzo[d]imidazole-2-yl)-2, 3-dimethyl-4-(2, 2, 2-trifluoroethoxy) 
pyridine-1ium.  
19 Deflazacort In base condition, the drug was readily degraded & produced and 21 hydroxy deflazacort 
(21-OH-DFZ) as degradation product. 
20 Nevirapine This drug degradation was observed in both heat & acidic condition. At acidic condition, 2-
(3-amino-4-methylpyridine-2-ylamino) nicotinic acid impurity was occurred. 
21 Cefditoren pivoxil This drug stable under the thermal & photolytic stress conditions, and also unstable at 
hydrolytic condition, 7 two degradant were produced. 
22 Sofosbuvir This drug stable under the thermal condition; susceptible to oxidative, photolytic & 
hydrolytic condition.  
23 Enflurane This drug under base stress condition, N-acetyl-L-cysteine S-conjugates impurity was 
produced. 
24 Paliperidone  This drug degradation observed at acid & base hydrolysis; 3-(1-allyl-1, 4-dihydropyridin-
4-yl)-5fluorobenzo isoxazole, and 5-(2-(4-(5-fluorobenzo isoxazol-3yl) piperidin-1yl) 
ethyl)-6-methylpyrimidin-4-(3H)-one were the degradation products produced under 
hydrolysis condition. 
25 Metoclopramide This drug is a photosensitive. Under the uv radiation, degradation reaction such as 
dechlorination & hydroxylation were occurred. 
26 Curcumin This drug is labile to base condition & able to withstand under the acidic, photolytic, 
oxidative, and thermal stress condition. In base condition, 8 degrading were occurred. 
27 Flupirtine maleate This drug at hydrolysis condition , 3 degradant were produced & identified as (2amino6 
[(4fluorobenzy)amino]pyridine-3-yl}carbamic acid,N-(4-fluorobenzyl)pyridine-2,3,6-
triamine & 5-[(4flourobenzyl) amino]-1,3-dihydro-2H-imidazo[4,5-b] pyridine-2-one 
28 Fidarestat  This drug is able to withstand under thermal & photolytic stress condition. These drug 
also unstable at hydrolysis & oxidative stress condition 
29 Ezetimibe This drug is stable at thermal, oxidative& photolytic condition, 4 degradant were produced 
at hydrolytic condition. 
30 Abacavir sulfate This drug degradation observed under oxidative & acid stress; in acid hydrolysis, 
C8H10N6 impurity was while C14H18N6O3 & C11H14N6O were produced at oxidative 
stress condition 
31 Finofibrate This drug is under hydrolysis & oxidative condition, drug undergoes degradation process. 
4 degradation products were occurred. 
32 Gefitinib This drug degradation observed at hydrolysis & oxidative condition; and also unstable at 
thermal condition. 
33 Emtricitabine This drug significantly degraded under oxidative& acidic stress condition; 3 major 
degrading were produced. 
34 Nintedanib This drug is stable at thermal & photolytic condition; labile to hydrolytic & oxidative 
condition; and in acid condition, 2 degrading, alkaline condition 1 degradation product, & 
oxidative condition 1 degradant were produced. 
35 Agomelatine  This drug is stable at thermal & photolytic condition; and also unstable at hydrolytic & 
oxidative. 
36 Hydrochlorothiazide This drug at under hydrolytic condition, 2 degrading was produced. 
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Conclusion 
Forced degradation studies provides information about 
degradation pathways and degradation product of active 
ingredient and its help to elucidate the structure of the 
degrants products. Forced degradation studies may or may 
not produce in storage condition, but they are used to select 
the suitable storage condition.it will helps to develop SIM 
(Stability indicating method). This forced degradation  
provide the information  will in turn help improve the 
formulation manufacturing process & determine the storage 
condition .as no specific set of condition is applicable to all 
drug substances and Products and regulatory guidance does 
not specify about the condition to be used. The aim of any 
plan used for forced degradation is to produce the desire 
amount of degradation i.e. 5-20%. This review article has 
been summarized to the best, to provide information about 
different regulatory guidance’s available for forced 
degradation studies, this method also perform stress testing 
studies under different accelerated condition, and stability & 
degradants produced under different stress testing 
condition for various drugs. 
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